F/M Investments’s Biogen BIIB Stock Holding History

F/M Investments’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$732K	Buy	3,389 +272	+9%	+$52K	0.04%	220
2026 Q1	$571K	Buy	3,117 +652	+26%	+$120K	0.04%	223
2025 Q4	$434K	Buy	+2,465	New	+$403K	0.02%	351

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

F/M Investments's BIIB Position: Q2 2026 in Review

F/M Investments increased its Biogen (BIIB) stake by 8.7% in Q2 2026, buying an estimated $52K and bringing the position to 3,389 shares worth $732K. The position accounts for 0.04% of the portfolio, ranked #220.

F/M Investments first reported a position in BIIB in Q4 2025 and has held it in 3 quarters since. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

F/M Investments held 3,389 shares of Biogen worth $732K as of Q2 2026.
F/M Investments bought 272 Biogen shares in Q2 2026, an estimated $52K.
Biogen made up 0.04% of F/M Investments's portfolio in Q2 2026, its #220 holding.
F/M Investments first reported a position in Biogen in Q4 2025 and has held it in 3 quarters since.
1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on F/M Investments's 13F filing for Q2 2026, filed 5 Aug 2026.